SIRT6 Activator Dosage: Manufacturer Guidance vs Human Trial Doses

There is no clinically established “anti-aging dose” of a SIRT6 activator. For the fucoidan-based DoNotAge SIRT6Activator, the numbers currently seen online come from three different evidence layers: manufacturer guidance, older human fucoidan studies and ongoing SIRT6-targeted aging trials.

Those numbers should not be blended together. A manufacturer dose is not automatically a trial-validated dose, and a dose used in a trial is not automatically proven optimal.

Dose	Source	Best interpretation
800 mg/day	DoNotAge lower-dose option / weight-tier guidance	Manufacturer protocol; not clinically validated for SIRT6 outcomes
1,600 mg/day	Current DoNotAge standard daily serving	Manufacturer's standard serving
2,400 mg/day	DoNotAge high-dose option; current aging research	Research dose selected for current human protocols
300 mg–4 g/day	Other human fucoidan studies	Different extracts, populations and endpoints; not dose-equivalent

What does DoNotAge currently recommend?

As of September 2026, DoNotAge lists 400 mg per capsule and calls 1,600 mg/day the standard daily dosage. Its current product system also offers 800, 1,600 and 2,400 mg/day options.

A separate DoNotAge dosing-journey page maps those doses to body weight:

• under 60 kg: 800 mg/day;
• 60–100 kg: 1,600 mg/day;
• over 100 kg: 2,400 mg/day.

No published randomized dose-response study has validated those weight bands as the optimal way to dose SIRT6Activator. They are manufacturer guidance, not a clinical dosing algorithm.

There is also a timing inconsistency in the current manufacturer guidance

The current DoNotAge product page gives split-dose instructions before the midday and evening meals, but the same page also says the “best time” is morning or early afternoon. Those statements are not fully aligned.

No product-specific pharmacokinetic or SIRT6 target-engagement study has shown that morning, midday, evening, fasting or fed administration produces superior human SIRT6 activation. The medically accurate position is therefore to report the manufacturer's directions without turning timing into an evidence-based mechanism.

Why 2.4 g/day matters

The most relevant current research dose is 2.4 g/day.

The peer-reviewed PROMETHEUS protocol includes DoNotAge.org SIRT6Activator® at 2.4 g/day as one component of a multimodal geroscience program [1]. The separate randomized Project SIRT6 Activator study also uses 2.4 g/day of fucoidan/SIRT6 activator against placebo for six months.

This means 2.4 g/day is a human research dose. It does not mean researchers have already demonstrated that it is more effective than 800 or 1,600 mg/day.

What doses have other human fucoidan studies used?

Fucoidan trials help with exposure and safety context, but the preparations are chemically different.

• A randomized osteoarthritis study used 300 mg/day of an F. vesiculosus extract containing about 85% fucoidan for 12 weeks [2].
• A 2025 prediabetes RCT used 1 g/day for 12 weeks [3].
• An immune-function pilot used 3 g/day of Cladosiphon okamuranus fucoidan for 12 weeks [4].
• Absorption work has used a single 3 g oral dose of mozuku-derived fucoidan [5].
• A current University of Rochester cancer-survivor study uses 4 g/day of F. vesiculosus fucoidan, but it is not a SIRT6 target-engagement trial.

A gram of one fucoidan is not necessarily pharmacologically equivalent to a gram of another. Species, molecular weight, sulfation, extraction and purity matter.

Can the mouse lifespan dose be converted to a human dose?

Not reliably. The 2025 Biashad preprint delivered fucoidan continuously through chow and drinking water to mice, with average intake around 278 mg/day in a roughly 30 g animal. That exposure is very high on a simple mg/kg basis.

Direct body-weight conversion is inappropriate for interspecies dosing, and even allometric scaling would not solve the bigger problem: the active circulating species and human SIRT6 dose-response are unknown.

The mouse experiment should therefore support biological plausibility, not a consumer dose calculation.

Should the daily dose be split?

DoNotAge currently gives twice-daily split instructions for the capsule product. There is no published comparison of once-daily versus divided dosing for SIRT6 target engagement, biological age or other aging outcomes.

The mouse lifespan study should not be used to validate the split schedule because the animals received ongoing dietary/water exposure rather than two discrete daily doses.

Does taking it with food improve absorption?

Human studies show that at least some orally administered fucoidan-derived material can be detected after ingestion, but absorption is low and variable [5].

No branded-product study has established that taking SIRT6Activator with a meal improves systemic exposure or SIRT6 activity.

Is more better?

No dose-response evidence supports that assumption. A higher dose means more exposure, but SIRT6 biology is context-dependent and fucoidan is chemically heterogeneous.

Until randomized dose-ranging human data exist, 2.4 g/day should be described as a studied dose—not the “best” or “most effective” dose.

What about bleeding risk at higher doses?

Fucoidans can show anticoagulant activity in laboratory systems. A small human study using 3 g/day for 12 days did not demonstrate a major predictable systemic anticoagulant effect, but it was small and short [6].

People using anticoagulants or antiplatelet drugs should not interpret the absence of a large signal in that pilot as proof of zero interaction risk.

Bottom line

1,600 mg/day is the current standard manufacturer serving; 2,400 mg/day is the key current SIRT6Activator research dose. Neither is a clinically proven optimal anti-aging dose.

The body-weight tiers and timing instructions are manufacturer protocols. Human dose-response and target-engagement data are still missing.

For trial design, see SIRT6 clinical trials. For risks, see SIRT6 activator side effects.